Kineret has been recommended by the European Union body for the treatment of various conditions.
The Hay:
European Union regulators on Thursday recommended two new treatments against Covid-19 for use in the bloc.
The European Medicines Agency (EMA) says Kineret, an immunosuppressive drug made by Orphan Biovitrum Sweden to treat inflammatory conditions, can “reduce damage to the lower airways, preventing the development of development of severe respiratory failure”.
It also says that GlaxoSmithKline’s Xevudy has been shown in one study to “significantly reduce hospitalizations and deaths in patients with at least one underlying condition”.
Kineret has been recommended by the EMA for the treatment of various conditions, with the agency expanding its list to include Covid-19.
The EMA says its use is recommended for adults “with pneumonia requiring supplemental oxygen … who are at risk of developing severe respiratory failure”.
Xevudy, developed by GSK with US company Vir Biotechnology, is the third EMA-supported drug that uses “monoclonal antibodies”, which are proteins designed to bind to the mutant protein of SARS-CoV- 2, the virus that causes Covid.
The agency said Xevudy would be recommended for most patients 12 years of age and older “who are at increased risk of severe disease.”
(Except for the title, this story has not been edited by NDTV staff and is published from an aggregated feed.)
